US 12,485,163 B2
Cancer therapy compositions and uses thereof
Steven Gregory Reed, Bellevue, WA (US); Darrick Albert Carter, Seattle, WA (US); Malcolm Scott Duthie, Sammamish, WA (US); Lars Peter Aksel Berglund, Seattle, WA (US); Jesse Hong-Sae Erasmus, Port Orchard, WA (US); and Jiho Kim, Seattle, WA (US)
Assigned to HDT Bio Corp., Seattle, WA (US)
Filed by HDT Bio Corp, Seattle, WA (US)
Filed on Mar. 15, 2024, as Appl. No. 18/607,029.
Application 18/607,029 is a continuation of application No. PCT/US2022/076304, filed on Sep. 12, 2022.
Claims priority of provisional application 63/302,360, filed on Jan. 24, 2022.
Claims priority of provisional application 63/247,167, filed on Sep. 22, 2021.
Prior Publication US 2024/0216493 A1, Jul. 4, 2024
Int. Cl. A61K 39/00 (2006.01); A61K 9/127 (2025.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 9/51 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/001193 (2018.08) [A61K 9/4858 (2013.01); A61K 9/5015 (2013.01); A61K 9/5115 (2013.01); A61K 9/5123 (2013.01); A61K 39/001156 (2018.08); A61K 39/001186 (2018.08); C12N 15/86 (2013.01); A61K 9/127 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/6075 (2013.01); C12N 2720/12143 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A composition comprising:
lipid nanoparticles, wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of about 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise:
a cationic lipid;
a hydrophilic surfactant; and
a hydrophobic surfactant; and
at least one nucleic acid, wherein the at least one nucleic acid comprises:
a sequence encoding for an RNA-dependent polymerase; and
a sequence encoding for a transmembrane-binding domain, an outer cell membrane-contacting domain, and an inner cell membrane-contacting domain of a prostein protein.